Variantyx, a leader in genomic precision medicine today, announced that it has secured additional funding from its portfolio of investors which includes Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners, 20/20 HealthCare Partners and Peregrine Ventures. The technology-driven provider of advanced genomic testing for genetic disorders, reproductive health and precision oncology markets continues to add many of the largest US healthcare systems to its customer base, rapidly growing its market share. The additional investment, which brings the total amount invested in Variantyx to over $120 million, will fuel further commercial expansion, enabling the company to build significant economic value and bring the power of precision medicine to larger numbers of patients at an accelerated rate.